Efficacy of SGLT2 inhibitor

Mechanism and efficacy of SGLT2 inhibitor in diabetes patients with renal anemia - SGLT2 inhibitor and renal anemia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000036183

Enrollment

Registered

2019-03-15

Start date

2018-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic nephropathy

Interventions

Canagliflozin 100mg daily, 12 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Type 2 diabetes (HbA1c<10.0%) 2. eGFR > 45 mL/min/1.73m2 3. Albuminuria > 30mg/gCr 4. Hb < 13.5g/dL 5. Age > 19 years old

Exclusion criteria

Exclusion criteria: 1. Intotelance for SGLT2 inhibitors 2. Past history of SGLT2 inhibitor before to 4 weeks at enrollment 3. Past history of administration of ESA before 12 weeks at enrollment 4. Ftn <50 ng/mL and TSAT <20% 5. HbA1c > 10.0% 6. Type 1 diabetes 7. eGFR<45mL/min/1.73m2 8. Pregnancy 9. alchol misuse 10. Severe ketosis, infection, and coma

Design outcomes

Primary

Measure	Time frame
Hemoglobin concentration, erythropoietin concentration	—

Secondary

Measure	Time frame
albuminuria, eGFR, urinary biomarkers	—

Countries

Japan

Contacts

Public ContactMasanori Abe

Nihon University Itabashi Hospital Nephrology, Hypertension and Endocrinology

abe.masanori@nihon-u.ac.jp03-3972-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026